MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.35
-0.25
-1.98%
Closed 19:49 01/26 EST
OPEN
12.79
PREV CLOSE
12.60
HIGH
13.33
LOW
12.21
VOLUME
1.94M
TURNOVER
--
52 WEEK HIGH
21.39
52 WEEK LOW
5.22
MARKET CAP
1.48B
P/E (TTM)
-36.5385
1D
5D
1M
3M
1Y
5Y
New Strong Buy Stocks for January 21st
ARCB, BCC, DVAX, FCX, and JBHT have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2022.
Zacks · 6d ago
Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows
Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, 
Benzinga · 01/19 17:53
Valneva extends losses as EU regulator awaits more data on COVID-19 shot
Valneva (VALN -3.7%) ADRs are trading lower for the fifth straight session after the European Medicines Agency (EMA) said that it was awaiting more data on the company’s COVID-19 vaccine
Seekingalpha · 01/19 16:41
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Popular Amongst Institutions?
If you want to know who really controls Dynavax Technologies Corporation ( NASDAQ:DVAX ), then you'll have to look at...
Simply Wall St. · 01/19 11:00
Top Pharmaceutical Stocks for Q1 2022
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.
Investopedia · 01/13 00:09
Dynavax Announces Initiation Of Phase 1 Clinical Trial For Its Shingles Vaccine Candidate
Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today outlined its strategic priorities for 2022, and
Benzinga · 01/10 13:05
Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today outlined its strategic priorities for 2022, and announced the newest candidate in its clinica...
PR Newswire · 01/10 13:00
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares of Dynav...
PR Newswire · 01/07 21:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DVAX stock price target is 30.25 with a high estimate of 38.00 and a low estimate of 25.00.
High38.00
Average30.25
Low25.00
Current 12.35
EPS
Actual
Estimate
-0.020.200.420.64
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 256
Institutional Holdings: 114.13M
% Owned: 95.15%
Shares Outstanding: 119.95M
TypeInstitutionsShares
Increased
51
9.72M
New
50
9.65M
Decreased
49
8.58M
Sold Out
21
4.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Chairman/Director
Scott Myers
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President/General Counsel
John Slebir
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Senior Vice President
Dong Yu
Director
Andrew Hack
Director
Elaine Sun
Independent Director
Francis Cano
Independent Director
Julie Eastland
Independent Director
Daniel Kisner
Independent Director
Brent MacGregor
Independent Director
Peter Paradiso
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
No Data
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), pertussis, and universal influenza.

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.